Increasing Returns in DrugDiscovery    Harnessing the Power of CellsTM                      Executive Overview
Focus:Provide pre-clinical development tools and methods to enable successfuloutcomes in early phase drug discovery. Fail...
Why Consider our Solutions Research proven solutions used by large Pharmas, Biotechs,  Academic and Government Labs. 2500...
ApplicationsHigh throughput and high content screening     Compound Testing     Toxicology Studies     DiscoveryCell ...
Cell Based Assays                                                                  FITC Labeled                           ...
Example hNP1TM Neural Progenitors to Sensory Neurons: Xiufang Guo, Severo Spradling, MariaStancescu, Stephen Lambert, Jame...
Key Product Category Links: Cell Based Assay-Cells, Media and 3-D Solutions, stem cell potency/toxicity Antibodies-Marke...
Competitive advantages Human Stem cell-derived: less animal studies, highly reproducible, cost-  effective, bulk cells/sy...
 Clear Understanding of where Neuromics/Vitro Biopharma  could have a positive impact.     More intense in vitro screeni...
Upcoming SlideShare
Loading in...5
×

Cell based assays presentation v3_03_2012

257

Published on

Update presentation on "increasing returns in drug discovery by harnessing the power of cells". Includes images/data/pubs of differentiating human sensory and dopaminergic neurons from hNP1 neural progenitors + osteoblasts and chondrocytes from human mesenchymal stem cells. Our platforms are ideal for high throughput screening and other drug discovery processes.

Published in: Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
257
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
12
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Cell based assays presentation v3_03_2012

  1. 1. Increasing Returns in DrugDiscovery Harnessing the Power of CellsTM Executive Overview
  2. 2. Focus:Provide pre-clinical development tools and methods to enable successfuloutcomes in early phase drug discovery. Failure is success whendetermined early.**90% of lead candidates identified by current in vitro systems fail to become drugsValue Summary: Physiologically relevant human stem-derived terminally differentiatedcells, cellular systems and primary cell lines  Better in vitro screening of targets and molecules =  Reduced animal model use  Shorten development timeline  Lower downstream costs *Expanding hN2 Primary Human Neurons stained with our chicken polyclonal antibody to Vimentin and DAPI (blue) MSCGro™ Media vs Alternative Executive Overview-V1-30-2013
  3. 3. Why Consider our Solutions Research proven solutions used by large Pharmas, Biotechs, Academic and Government Labs. 2500+ customers  Publications/Testimonials Lower per well costs-we can aggressively discount cells and media Customer success focused  Expert technical support  Detailed protocols and methods  Quick replacements and reorders  Large expert resource network  Published expert input  Non confidential; customer feedback and data sharing through social media outlets and blogs Executive Overview-V2-30-2013
  4. 4. ApplicationsHigh throughput and high content screening  Compound Testing  Toxicology Studies  DiscoveryCell expansion, differentiation and migrationstudiesIn Vivo cell ImagingImages: To demonstrate the capabilities of the NIR-FLIVO® 747 apoptosis Images: (A) UCB Derived hMSCs cultured using our lowtracer, adult wild-type Balb/c mice were either inoculated with HSV-1 virus, Serum MSCGro media and then differentiated using ourwhich is known to induce apoptosis in the brain, or given a sham treatment. Oetsogenic Differentiation Media.Seven days after viral inoculation, the mice were injected intravenously witheither the NIR-FLIVO® 747apoptosis tracer (cat. KF17368), the NIR-FLIVO®747 free dye (cat. KF17370, DyLight®747), or no reagent. Executive Overview-V3-03-2013
  5. 5. Cell Based Assays FITC Labeled hChondrocytes Tools Include: • Growth- Differentiation Factors • High- FITC Labeled 3-D Solutions Performance hOsteoblasts Media Human Mesenchymal • Transfection Stem Cells-Green Kits Fluorescent-Labeled • Markers • 3-D hDopamingergic Fibers/ECMs Neurons Derived using hGNDF Migration AssaysComing soon! Courtesy of EssenSPIO-Labeled hN2 Human Neurons BiosciencesCells for in-vivo (mixed) stained withImaging MAP-2 , Courtesy of Dr. Gerry Shaw, UF hNP1 Neural Progenitors-100% Confluency Testimonial: got 10 million cells total after extraction from the tissue. At Day 4 they all developed long axons. Thank you so much for the replacement." Dr. Lidia Gardner, University of Tennessee HSC. Executive Overview-V3-03-2013
  6. 6. Example hNP1TM Neural Progenitors to Sensory Neurons: Xiufang Guo, Severo Spradling, MariaStancescu, Stephen Lambert, James J. Hickman. Derivation of sensory neurons and neural creststem cells from human neural progenitor hNP1. Biomaterials, In Press, Corrected Proof,Mar2013.doi:10.1016/j.biomaterials.2013.02.061.Images: Phase contrast images of the cultures before and after the sensory neuron induction. A) hNP1 culture before sensoryinduction. B) hNP1 culture 10 days after sensory induction. C) hNP1 culture 30 days after sensory induction. Neuronal clusters andaxonal bundles, which resemble rat DRG cell cultures, were typically observed. D) For comparison, an image of a rat embryonic DRGcell culture at 7 DIV is provided. Executive Overview-V3-03-2013
  7. 7. Key Product Category Links: Cell Based Assay-Cells, Media and 3-D Solutions, stem cell potency/toxicity Antibodies-Markers-internally developed markers for neuroscience, immune response, cancer, Autoimmune disease and stem cell research Apoptosis Research Reagents -includes: detection kits, antibodies and proteins Proteins Recombinant and natural proteins-includes a wide selection of cell growth factors. Transfection & Reagents-Gene Expression Analysis, engineered cell lines for custom applications Executive Overview-V2-30-2013
  8. 8. Competitive advantages Human Stem cell-derived: less animal studies, highly reproducible, cost- effective, bulk cells/systems of in-vivo replicates as in-vitro, defined systems. Expertise in Stem Cell Differentiation: Substantial experience in differentiation, trans-differentiation and characterization NSC & MSC-derived cell systems: Neurons, DA and mixed, 5-HT, ACh, NE, GABA- nergic, etc. MSC-derived chondrocytes, osteoblasts and endothelial cells. IPSC-based cell-line generation platform: The classic four-gene method of Grudin and Yamanaka, the 2012 Nobel Prize winners, can be replaced by over- expression of Oct 3/4 only in adult stem cells & Vitro Biopharma has a proprietary position (with licensing opportunities). IPSCs platform provides capacity for any human cell lineage. Transfection Expertise: This allows us to provide custom engineered cell systems for HTP screening. Cell labeling: Stem cell/derivative labeling by fluorescent, magnetic and nanoparticle-based probes. Ideal for in-vivo imaging, HTP and marker analysis. Technical Support: Substantial technical support in all phases of projects. Executive Overview-V2-30-2013
  9. 9.  Clear Understanding of where Neuromics/Vitro Biopharma could have a positive impact.  More intense in vitro screening of compounds and targets.  Better candidates for downstream processes.  Tools for in vivo assays Propose solutions based on this understanding Follow up, tweak and improvePete ShusterCEO and OwnerDirect Phone: 612-801-1007pshuster@neuromics.com Executive Overview-V2-30-2013
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×